Bristol-Myers Squibb (BMY) announced after the bell Wednesday that it has suspended study drug administration in an ongoing Phase II study of BMS-986094, a nucleotide polymerase inhibitor in development for the treatment of hepatitis C.
Bristol-Myers Squibb gapped open sharply lower Thursday and slipped further during the second half of the session. The stock closed down by 3.05 at $32.55 on the highest volume of the year and fell to over a 2-month low.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.